MXPA00003997A - Articulos de fabricacion. - Google Patents

Articulos de fabricacion.

Info

Publication number
MXPA00003997A
MXPA00003997A MXPA00003997A MXPA00003997A MXPA00003997A MX PA00003997 A MXPA00003997 A MX PA00003997A MX PA00003997 A MXPA00003997 A MX PA00003997A MX PA00003997 A MXPA00003997 A MX PA00003997A MX PA00003997 A MXPA00003997 A MX PA00003997A
Authority
MX
Mexico
Prior art keywords
manufacture
articles
relates
present
pharmaceutical
Prior art date
Application number
MXPA00003997A
Other languages
English (en)
Inventor
Thomas Emmick Jeffrey
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA00003997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of MXPA00003997A publication Critical patent/MXPA00003997A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Articulos de fabricacion farmaceuticos que usan inhibidores de encina fosfodiesterasa (PDE) altamente selectivos. La presente invencion se refiere inhibidores potentes de fosfodiesterasa tipo (PDES) especifica para 3', 5'-monosfosfato de guanosina ciclico, que cuando se incorporan en n producto farmaceutico en una dosificacion unitaria de aproximadamente 1 a aproximadamente 20 mg son utiles para el tratamiento de la disfuncion sexual. Los articulos de fabricacion descritos aqui se caracterizan por la inhibicion de PDE5 selectiva y, de acuerdo con esto, proporcionan un beneficio en areas terapeuticas en las que se desca la inhibicion de PDES, con minimizacion o eliminacion de efectos secundarios de otras enzimas fosfodiesterasa.
MXPA00003997A 1999-04-30 2000-04-25 Articulos de fabricacion. MXPA00003997A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
MXPA00003997A true MXPA00003997A (es) 2002-03-08

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA00003997A MXPA00003997A (es) 1999-04-30 2000-04-25 Articulos de fabricacion.
MXPA01010837A MXPA01010837A (es) 1999-04-30 2000-04-26 Forma de dosificacion unitaria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA01010837A MXPA01010837A (es) 1999-04-30 2000-04-26 Forma de dosificacion unitaria.

Country Status (47)

Country Link
EP (2) EP1173181B3 (es)
JP (2) JP2000336043A (es)
KR (2) KR20010020779A (es)
CN (2) CN1196487C (es)
AT (1) ATE251908T1 (es)
AU (3) AU3012900A (es)
BE (1) BE1012957A5 (es)
BR (2) BR0010181A (es)
CA (2) CA2307101C (es)
CH (2) CH692478A5 (es)
CO (1) CO5170493A1 (es)
CZ (1) CZ296534B6 (es)
DE (3) DE60005940T3 (es)
DK (2) DK200000677A (es)
DZ (1) DZ3171A1 (es)
EA (2) EA200000355A3 (es)
ES (2) ES2187234A1 (es)
FI (1) FI20000976A (es)
FR (1) FR2795646B1 (es)
GB (1) GB2351663A (es)
GR (1) GR1003575B (es)
HK (1) HK1041204B (es)
HR (2) HRP20000243A2 (es)
HU (2) HUP0001632A3 (es)
ID (1) ID25704A (es)
IE (1) IE20000315A1 (es)
IL (3) IL135817A0 (es)
IT (1) ITMI20000922A1 (es)
LT (1) LT4758B (es)
LU (1) LU90569B1 (es)
LV (1) LV12560B (es)
MX (2) MXPA00003997A (es)
NL (1) NL1015027C2 (es)
NO (2) NO20002097L (es)
NZ (2) NZ514882A (es)
PE (1) PE20010071A1 (es)
PL (2) PL339897A1 (es)
PT (2) PT1173181E (es)
SE (1) SE0001518L (es)
SG (1) SG98384A1 (es)
SI (2) SI1173181T1 (es)
SK (1) SK285415B6 (es)
SV (1) SV2002000055A (es)
TR (1) TR200001132A2 (es)
UA (1) UA72248C2 (es)
WO (1) WO2000066099A2 (es)
ZA (2) ZA200002058B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
JP2004533402A (ja) * 2000-06-08 2004-11-04 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅｖインヒビターとしての四環系ジケトピペラジン化合物
WO2002010166A1 (en) * 2000-08-02 2002-02-07 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
CA2445620C (en) 2001-06-05 2008-07-08 Lilly Icos Llc Tetracyclic compounds as pde5-inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
KR20080112285A (ko) 2006-03-28 2008-12-24 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
EP3749370A1 (de) * 2018-02-07 2020-12-16 Smawa GmbH Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
BR9709230A (pt) 1996-05-10 1999-08-10 Icos Corp Composto
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
AU4663100A (en) * 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder

Also Published As

Publication number Publication date
JP2000336043A (ja) 2000-12-05
EA200000355A2 (ru) 2000-10-30
KR20010020779A (ko) 2001-03-15
CH1173181H1 (es) 2019-07-15
LT2000035A (en) 2000-11-27
HK1041204B (zh) 2004-03-05
NZ514882A (en) 2003-08-29
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
ES2187234A1 (es) 2003-05-16
TR200001132A3 (tr) 2001-01-22
DE60005940T3 (de) 2015-08-27
WO2000066099A3 (en) 2001-01-18
CN1292264A (zh) 2001-04-25
PT102457A (pt) 2000-11-30
FI20000976A (fi) 2000-10-30
AU3012900A (en) 2000-11-02
KR100577057B1 (ko) 2006-05-10
CN1384746A (zh) 2002-12-11
LU90569B1 (fr) 2002-02-27
KR20020008396A (ko) 2002-01-30
BR0003046A (pt) 2002-07-23
CN1196487C (zh) 2005-04-13
DE60005940D1 (de) 2003-11-20
NO322013B3 (no) 2017-11-06
MXPA01010837A (es) 2002-11-07
ZA200002058B (en) 2000-11-02
UA72248C2 (en) 2005-02-15
SV2002000055A (es) 2002-07-03
LV12560B (en) 2001-04-20
NL1015027A1 (nl) 2000-10-31
AU769946B2 (en) 2004-02-12
IE20000315A1 (en) 2001-03-07
DE20007861U1 (de) 2000-08-24
DE10021266A1 (de) 2000-11-16
NO20015275L (no) 2001-12-06
ITMI20000922A0 (it) 2000-04-26
SE0001518D0 (sv) 2000-04-26
GR20000100153A (el) 2000-12-29
NO20002097L (no) 2001-10-26
IL146098A (en) 2007-06-03
AU2004201988A1 (en) 2004-06-10
HU230369B1 (hu) 2016-03-29
PT1173181E (pt) 2004-02-27
EP1173181A2 (en) 2002-01-23
ID25704A (id) 2000-11-02
JP4975214B2 (ja) 2012-07-11
CA2307101C (en) 2003-01-28
JP2002543116A (ja) 2002-12-17
PE20010071A1 (es) 2001-03-22
DE60005940T2 (de) 2004-07-29
HRP20000243A2 (en) 2001-12-31
FI20000976A0 (fi) 2000-04-26
CO5170493A1 (es) 2002-06-27
CA2371684A1 (en) 2000-11-09
NL1015027C2 (nl) 2001-02-14
IL146098A0 (en) 2002-07-25
AU4490800A (en) 2000-11-17
SI1173181T1 (en) 2004-04-30
HUP0001632A3 (en) 2001-12-28
NO20002097D0 (no) 2000-04-25
BR0010181A (pt) 2003-02-25
DK200000677A (da) 2000-10-31
WO2000066099A2 (en) 2000-11-09
NO20015275D0 (no) 2001-10-29
HUP0001632A2 (hu) 2001-05-28
IL135817A0 (en) 2001-05-20
HUP0200912A3 (en) 2003-07-28
SI20361A (sl) 2001-04-30
FR2795646B1 (fr) 2002-08-16
GR1003575B (el) 2001-05-14
EA200000355A3 (ru) 2001-02-26
PL197813B1 (pl) 2008-04-30
SK15632001A3 (sk) 2002-02-05
TR200001132A2 (tr) 2001-01-22
DZ3171A1 (es) 2000-11-09
BE1012957A5 (fr) 2001-06-05
ATE251908T1 (de) 2003-11-15
NZ504163A (en) 2001-11-30
DK1173181T3 (da) 2004-02-16
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
SG98384A1 (en) 2003-09-19
CZ296534B6 (cs) 2006-04-12
NO322013B1 (no) 2006-08-07
ITMI20000922A1 (it) 2001-10-26
FR2795646A1 (fr) 2001-01-05
HU0200912D0 (en) 2002-04-29
EP1173181B1 (en) 2003-10-15
ES2208317T3 (es) 2004-06-16
ZA200108900B (en) 2003-03-26
GB0010199D0 (en) 2000-06-14
LV12560A (en) 2000-11-20
EP1173181B3 (en) 2015-03-25
GB2351663A (en) 2001-01-10
LT4758B (lt) 2001-02-26
ES2208317T7 (es) 2015-09-15
EP1415652A2 (en) 2004-05-06
CZ20013879A3 (cs) 2002-04-17
HRP20010778B1 (en) 2005-04-30
EP1415652A3 (en) 2004-05-12
HUP0200912A2 (en) 2002-08-28
PL352629A1 (en) 2003-08-25
EA200101008A1 (ru) 2002-04-25
AU769946C (en) 2005-01-13
CH692478A5 (de) 2002-07-15
SE0001518L (sv) 2000-10-31
DK1173181T6 (en) 2015-04-27
CA2307101A1 (en) 2000-10-30
PL339897A1 (en) 2000-11-06
CA2371684C (en) 2007-10-23
SK285415B6 (sk) 2007-01-04

Similar Documents

Publication Publication Date Title
MXPA00003997A (es) Articulos de fabricacion.
WO2001080860A3 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction